← SynDRA

PIMAVANSERIN

SynDRA canonical compound SYN0033695 — structure-anchored drug synonym record

All known targets

• HTR2A
• HTR2C
• DRD2

Mechanisms of action (all sources)

• Serotonin receptor inverse agonist
• HTR2A INVERSE AGONIST
• Serotonin 2a (5-HT2a) receptor inverse agonist
• HTR2A AGONIST
• HTR2C AGONIST
• HTR2A MODULATOR

Drug classes

• Atypical Antipsychotic
• Anti-Dyskinesia Agents
• Antiparkinson Agents
• Antipsychotic Agents
• Central Nervous System Agents
• Central Nervous System Depressants
• Neurotransmitter Agents
• Psychotropic Drugs
• Serotonin 5-HT2 Receptor Antagonists
• Serotonin Agents
• Serotonin Antagonists
• Tranquilizing Agents

ATC classes

• N05A · ANTIPSYCHOTICS

Cross-references

• PubChem CID: 10071196
• ChEMBL: CHEMBL2111101
• DrugBank: DB05316
• ChEBI: CHEBI:133017
• KEGG: D08969
• RxNorm: 1791685
• PDB: A1L11
• Wikipedia: Pimavanserin
• TTD: D0J8JP
• LINCS BRD: BRD-K83405785

Synonyms

• pimavanserin tartrate
• ACP-103
• nuplazid
• Pimavanserine
• Pimavanserina
• ST51054136
• AC-5273
• I14-1981
• 1-[(4-fluorophenyl)methyl]-1-(1-methyl-4-piperidyl)-3-[[4-(2-methylpropoxy)phenyl]methyl]urea
• Nuplazid
• Pimavanserin tartrate
• UNII-NA83F1SJSR
• 706782-28-7 (tartrate)
• NA83F1SJSR
• Pimavanserin tartrate [USAN]
• Bis(1-(4-Fluorobenzyl)-1-(1-methylpiperidin-4-yl)-3-(4-(2-methylpropoxy)benzyl)urea) (2R,3R)-2,3-dihydroxybutanedioate
• Pimavanserin tartrate (USAN)
• 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)urea, ((2R,3R)-2,3-dihydroxysuccinate) (2:1)
• Nuplazide (TN)
• pimavanserin hemitartrate
• DTXSID50220958
• CHEBI:133014
• HMS3886L06
• HY-14557A
• Pimavanserin Dihydroxysuccinate(2:1)
• AKOS027327334
• CCG-270608
• CS-7954
• 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)urea (2R,3R)-2,3-dihydroxysuccinate
• AC-29901
• AS-56699
• N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1)
• Urea, N-((4-fluorophenyl)methyl)-N-(1-methyl-4-piperidinyl)-N'-((4-(2-methylpropoxy)phenyl)methyl)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1)
• D08969
• Q27284759
• bis(4-{[(4-fluorophenyl)methyl]({[4-(2-methylpropoxy)phenyl]methyl}carbamoyl)amino}-1-methylpiperidin-1-ium) (2R,3R)-2,3-dihydroxybutanedioate
• bis{N-[(4-fluorophenyl)methyl]-N-(1-methylpiperidin-4-yl)-N'-{[4-(2-methylpropoxy)phenyl]methyl}urea} (2R,3R)-2,3-dihydroxybutanedioate
• JZ963P0DIK

Reported adverse events

• Confusional state
• Constipation
• Gait disturbance
• Gastrointestinal disorder
• Hallucination
• Nausea